Skip to main content
OpenTrials
Completed

NCT Number: NCT06525935

A Study of Enicepatide (CT-388) in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity

This is a multi-center, randomized, double-blind, placebo-controlled, parallel group dose-finding study to evaluate the efficacy and safety of enicepatide at low, middle, and high doses in participants with obesity or who are overweight with at least one weight-related comorbidity.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Alabama Clinical Therapeutics, LLC, Birmingham, Alabama, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female, 18 to 75 years of age
  • Body mass index (BMI) ≥30.0 kg/m2, OR BMI ≥27.0 and <30.0 kg/m2 and previously diagnosed with at least 1 of the following weight-related comorbidities, such as: prediabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease
  • At least one self-reported unsuccessful effort to lose body weight

Exclusion criteria

  • Prior history/diagnosis/lab evidence of any type of diabetes mellitus (e.g., Type 1, Type 2, gestational), or a history of ketoacidosis or hyperosmolar state
  • Self-reported body weight change of >5 kg within 3 months before randomization
  • Any unbalanced/extreme diets within 3 months of the screening visit, or plan to be on such diets during the study
  • Current or recent participation in an organized weight reduction program
  • Current or recent use of any treatment that promotes weight loss or glucose metabolism
  • Current or recent use of treatment that may cause weight gain
  • Prior or planned surgical treatment for obesity
  • Clinically significant or active gastric emptying abnormality, malabsorption, or chronic use of medications that directly affect GI motility
  • History of chronic pancreatitis or acute pancreatitis within 6 months before screening
  • Have obesity induced by other endocrinologic disorders (e.g., Cushing syndrome) or diagnosed monogenetic or syndromic forms of obesity
  • History of major depressive disorder within 2 years of screening, or any history/diagnosis of other severe psychiatric conditions (Note: Prospective participants with depression or anxiety whose disease state, in the opinion of the Investigator, is considered stable and expected to remain stable throughout the course of the study, may be considered for inclusion)
  • Family or personal history of medullary thyroid carcinoma
  • Serum calcitonin ≥ 20 ng/L
  • Women who are pregnant, breastfeeding, or intend to become pregnant, or are of childbearing potential and not using a highly effective contraceptive method

Treatment and study plan

Placebo

Drug

Placebo will be volume- matched and administered subcutaneously (SC) once weekly.

Enicepatide

Drug

Enicepatide will be administered subcutaneously (SC) once weekly at the randomized dosing regimen.

Other names: CT-388, RO7795068, RG6640

Primary outcomes

  1. Percent Change in Body Weight from Baseline to Week 48

    Time frame: Baseline to Week 48

Secondary outcomes

  1. Percentage of Participants with Body Weight Reduction ≥5%, ≥10%, ≥15%, ≥20%, and ≥25% from Baseline to Week 48

    Time frame: Baseline and Week 48

  2. Absolute Change in Body Weight (kg) from Baseline to Week 48

    Time frame: Baseline to Week 48

  3. Percent Change in Body Weight from Baseline to Week 48 by Obesity Class

    Time frame: Baseline to Week 48

  4. Change in Body Mass Index (BMI) from Baseline to Week 48

    Time frame: Baseline to Week 48

  5. Change in Waist Circumference from Baseline to Week 48

    Time frame: Baseline to Week 48

  6. Change in Hip Circumference from Baseline to Week 48

    Time frame: Baseline to Week 48

  7. Change in Waist-to-Hip Ratio from Baseline to Week 48

    Time frame: Baseline to Week 48

  8. Change in Waist-to-Height Ratio from Baseline to Week 48

    Time frame: Baseline to Week 48

  9. Change in Glycated Hemoglobin (HbA1c) from Baseline to Week 48

    Time frame: Baseline to Week 48

  10. Change in Fasting Plasma Glucose from Baseline to Week 48

    Time frame: Baseline to Week 48

  11. Change in Fasting Insulin from Baseline to Week 48

    Time frame: Baseline to Week 48

  12. Change in Fasting C-peptide from Baseline to Week 48

    Time frame: Baseline to Week 48

  13. Change in Fasting Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) from Baseline to Week 48

    Time frame: Baseline to Week 48

  14. Change in Quantitative Insulin Sensitivity Check Index (QUICKI) from Baseline to Week 48

    Time frame: Baseline to Week 48

  15. Percentage of Participants with Shift in Glycemic Status from Baseline to Week 48, Based on Fasting Plasma Glucose and HbA1c

    Time frame: Baseline and Week 48

Sponsors and collaborators

Lead sponsor

Carmot Therapeutics, Inc.

Industry

Collaborators

  • Hoffmann-La Roche

Registry information

Official study title

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of Once-Weekly CT-388 Administered for 48 Weeks to Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Jul 29, 2024
Registry last updated
Apr 17, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.